Ivadal

Quick links to important sections

Ivadal

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivadal

Quick Facts

Property Description
Active Ingredient Zolpidem Tartrate (INN)
Form Oral formulation (typically film-coated tablet)
Pharmacological Class Sedative-Hypnotic (Nonbenzodiazepine)
General Purpose Facilitating the initiation of sleep
Origin Synthetic, Imidazopyridine derivative

Ivadal: Defining the Nonbenzodiazepine Sedative-Hypnotic

Ivadal is a branded pharmaceutical product whose active substance is Zolpidem Tartrate, a synthetic compound classified within the sedative-hypnotic pharmacological group. This medicine is a single-ingredient product belonging to the distinct family of Z-drugs, specifically identified as an imidazopyridine derivative. This nonbenzodiazepine classification is a key structural differentiation, although it shares the functional purpose of promoting rest. As a prescription-only medicine, Zolpidem is designated as a federally controlled substance, Schedule IV, a classification that indicates its recognized medical utility alongside a potential for abuse or dependence.

Composition, Form, and General Therapeutic Purpose

The formulation of Ivadal consists of Zolpidem Tartrate combined with necessary solid pharmaceutical excipients, engineered as an oral formulation typically supplied as a film-coated tablet. The immediate-release nature of the standard tablet is primarily designed to aid in the quick onset of sleep, a function clinically recognized for its ability to reduce the time required to fall asleep. This general therapeutic purpose is achieved through the drug’s action as a positive allosteric modulator at the brain's GABAA receptors. By enhancing the natural inhibitory signals of the central nervous system, Ivadal ultimately facilitates a faster transition into a state of sleep.

Regulatory References

  1. Zolpidem on NIH/DailyMed

What side effects are possible with Ivadal?

Adverse Reaction Scope

The official safety profile for Ivadal (Zolpidem Tartrate) is defined by government regulatory documents, classifying possible effects by frequency and the body system affected.

Classification Scope Officially Documented Characteristics
Key Adverse Reaction Categories Effects are concentrated in the Nervous System (e.g., headache, somnolence, dizziness) and Psychiatric systems (e.g., hallucination, agitation, nightmare). Gastro-Intestinal (diarrhea, nausea) and Musculoskeletal (back pain, myalgia) effects are also listed.
Frequency Classification Common effects include drowsiness, headache, dizziness, and certain gastrointestinal disturbances. Uncommon effects include confusional state, irritability, and blurred vision. Rare effects include liver injury, gait disturbance, and falls.
Serious Adverse Reactions Regulatory labels highlight potentially fatal outcomes, including Complex Sleep Behaviors (e.g., sleep-driving, preparing food, making calls, with amnesia for the event) and Severe Allergic Reactions (anaphylaxis/angioedema, which can cause life-threatening airway obstruction). The label also notes the risk of worsening depression and suicidal thinking.
Population-Specific Safety Older adults are documented as having heightened sensitivity to effects such as confusion and dizziness, with an increased risk of falls. The medicine is contraindicated in patients with severe hepatic insufficiency due to the risk of precipitating hepatic encephalopathy.
Exposure-Related Patterns The risk of next-day impairment (e.g., reduced motor coordination and alertness) increases if insufficient time (less than 7–8 hours) is available for sleep after taking the drug. The potential for developing tolerance and dependence (with subsequent withdrawal symptoms) is associated with the duration of treatment.

Safety-Related Restrictions and Limitations

Specific high-level safety constraints are established in regulatory documentation. The medicine is contraindicated in conditions such as severe hepatic insufficiency, a history of complex sleep behaviors after zolpidem use, and acute or severe respiratory depression. Concomitant use with alcohol or other Central Nervous System depressants is documented to increase the risk of severe sedation and complex behaviors.

Connection to the Overall Safety Profile

The official safety information systematically structures the risk profile by defining the full spectrum of possible effects, from frequently reported to rare but serious outcomes. This regulatory framework emphasizes key high-risk events through explicit warnings and establishes definitive limitations for use in vulnerable populations and when combined with other CNS depressants, ensuring a standardized, non-advisory description of documented safety characteristics.

Overdose and Emergency Response

The official regulatory documentation defines the Ivadal (Zolpidem Tartrate) overdose profile by the presentation of profound Central Nervous System (CNS) depression. Documented manifestations range from somnolence and severe drowsiness to significant impairment of consciousness and potentially coma. Other clinical signs noted in official labeling may include staggering and severe nausea or vomiting.

Overdose is considered a medical emergency because of the risk of life-threatening systemic compromise. Authorities warn of the potential for severe respiratory compromise and cardiovascular compromise, with fatal outcomes reported in postmarketing experience. Because of these serious risks, the official labeling strictly mandates that individuals seek immediate medical attention or get emergency help at once when an overdose is suspected.

Management involves providing general symptomatic and supportive measures. Where appropriate, procedural steps include immediate gastric lavage and the administration of intravenous fluids. The regulatory guidance requires continuous monitoring of vital signs, including respiration, pulse, and blood pressure, until the patient is stable. While Flumazenil may reduce the sedative effect, its use is cautioned, as it may contribute to the appearance of convulsions. Increased risk of severe effects is noted when Ivadal is combined with alcohol or other CNS depressant agents.

Therapeutic Uses of Ivadal

What Ivadal Treats: Main Uses and Benefits

Ivadal is commonly used to help manage the symptom clusters associated with insomnia, a condition characterized by difficulties falling asleep or staying asleep. The medication is applied across therapeutic domains involving certain distressing symptoms.

The primary therapeutic use is to provide supportive relief for symptoms of difficulty falling asleep and nocturnal awakenings. It is generally used to help address these symptoms when they interfere with daily functioning, providing short-term symptomatic assistance. The core role of Ivadal is to provide support during episodes of acute or recurrent insomnia.

Ivadal is considered relevant for easing symptoms related to both transient (temporary) and chronic forms of insomnia in adult patients. This supportive relief is considered relevant for managing sleep disruption and assists with maintaining functional stability.


Quick Fact: Relief for Difficulty Falling Asleep The primary benefit is assisting with the process of falling asleep, and it is commonly used when patients experience a long delay between lying down and achieving rest.


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Non-Eligibility for Ivadal Use

Ivadal (Zolpidem) is officially approved for use in adult patients 18 years of age and older. Regulatory documents establish strict population rules, defining groups that are excluded or require special consideration.

Classification Population Status
Populations Excluded (Contraindicated)
Hypersensitivity Known allergy to zolpidem or formulation ingredients
Sleep Behaviors History of complex sleep behaviors (e.g., "sleep-driving") after taking zolpidem
Organ Function Severe hepatic insufficiency (severe liver impairment)
Comorbidity (Non-US Labeling) Sleep apnoea syndrome, Myasthenia gravis, or Acute/Severe respiratory insufficiency
Populations Requiring Special Consideration
Age (Geriatric) Older or debilitated patients
Organ Function Mild to moderate hepatic impairment
Gender Adult women, due to known differences in drug clearance
Not Recommended/Not Established
Pediatric Use Children and adolescents under 18 years of age; safety and effectiveness not established
Reproductive Status Pregnancy and lactation (breastfeeding)

What should I know about interactions with other medicines?

Ivadal (zolpidem) may interact with other medicines, substances, or products, primarily by enhancing central nervous system (CNS) depressant effects and through changes in its metabolism.

Interactions Causing Increased CNS Depression

Concomitant use with alcohol is not recommended, as it significantly enhances the sedative effect, increasing the risk of drowsiness, next-day impairment, and complex sleep behaviors like "sleep-driving." Other CNS depressants—including opioids, benzodiazepines, certain antidepressants, antipsychotics, and some antihistamines—may have an additive effect, causing increased sedation, respiratory depression, and psychomotor impairment. When Ivadal is combined with opioids, the risk of severe respiratory depression, coma, and death is elevated, and co-prescribing should be limited to the lowest effective doses for the minimum duration.

Metabolic Interactions

Ivadal is metabolized by hepatic cytochrome P450 enzymes, primarily CYP3A4. Medicines that affect this enzyme can alter Ivadal's concentration in the body.

Interaction Mechanism Examples Effect on Ivadal
Enzyme Inhibitors Itraconazole May increase the effects of Ivadal.
Enzyme Inducers Rifampin May decrease the effectiveness of Ivadal.

Taking Ivadal with less than 7 to 8 hours remaining before an activity requiring full mental alertness is considered an interaction-related constraint, as it increases the risk of functional impairment.

Mechanism of Action

Ivadal (zolpidem) functions as a GABAergic positive allosteric modulator, primarily targeting the GABA A receptor complex within the central nervous system. Specifically, it exhibits high affinity for the BZ1 (omega1) receptor site, which is predominantly associated with GABA A receptors containing the alpha1 subunit (alpha1beta2gamma2 and alpha1beta3gamma2 subtypes).

Ivadal’s interaction is that of a non-benzodiazepine agonist at this binding site. This allosteric modification enhances the affinity of the GABA A receptor for its endogenous ligand, gamma-aminobutyric acid ( GABA). This action potentiates the inhibitory neurotransmission mediated by GABA.

Intracellularly, the increased GABA affinity results in a greater frequency of chloride channel opening. This Cl^- influx across the neuronal membrane causes hyperpolarization of the post-synaptic neuron. The resulting reduction in neuronal excitability modulates signaling pathways, leading to a system-level physiological consequence of central nervous system depression.

Dosage and Administration Information

How Ivadal is Used

Ivadal (Zolpidem Tartrate) is administered strictly through the oral route as an immediate-release tablet and is indicated for short-term treatment of insomnia. Official administration guidelines are defined by specific dosing, timing, and duration constraints to ensure proper use.

Official Administration Guidelines

Instruction Detail
Administration Route Oral (tablet swallowed whole).
Timing Constraint Must be taken only when ready to sleep and with a commitment to 7 to 8 hours of sleep remaining.
Food Condition Should not be taken with or immediately after a meal, as food intake may delay the onset of the drug's effect.
Frequency A single dose is taken once daily and must not be re-administered during the same night.
Maximum Duration Treatment should be as short as possible, generally not exceeding four weeks, including any necessary tapering period.

Standard Dosing and Special Populations

The standard adult dosing range is 5 mg to 10 mg taken once nightly. The maximum recommended dose for the immediate-release tablet is 10 mg per day. The starting dose may differ based on sex; the recommended initial dose for adult women is 5 mg due to differences in drug clearance, while adult men may start with either 5 mg or 10 mg.

Specific dosage adjustments are required for certain populations. Older adults (geriatric patients) and individuals with hepatic impairment are officially recommended to start with the lower dose of 5 mg once daily. Ivadal is not recommended for use in the pediatric population (below 18 years of age).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ivadal

The official research base for Ivadal (Zolpidem) includes Randomized Controlled Trials (RCTs) and other scientific evidence. These are studies where participants with insomnia were randomly assigned to receive either the active medicine or an inactive placebo. The evidence is derived from reports published in peer-reviewed scientific literature and summaries provided by regulatory agencies, which contributes to understanding how symptoms evolved in the observed populations. Study results reflect the specific conditions under which they were conducted.


Evidence for Use in Difficulties Falling Asleep (Sleep Initiation)

Research examined Ivadal in trials assessing short-term or episodic symptom patterns in adults experiencing trouble falling asleep. These studies monitored key outcomes reflecting daily functioning or activity level, such as Sleep Latency (the time it takes to fall asleep), using both objective (Polysomnography or PSG) and patient-reported methods.

The findings describe patterns observed in the studies related to measurements of sleep onset time in the active group compared to the placebo group. Trials reported how symptoms evolved in the observed populations during the short-term study period. Research highlights changes measured during the study period, which contribute to the broader evidence landscape regarding sleep onset.

However, follow-up durations were limited in most of these core trials. The research exploring short-term symptom changes typically lasted only a few weeks (e.g., 7 to 35 nights). This means that data for long-term outcomes are not sufficient to describe sustained patterns or whether the initial observations continue over many months. Evidence contributes to the broader evidence landscape but does not determine whether an individual will respond similarly over extended periods.


Evidence for Sleep Maintenance (Nocturnal Awakenings)

Ivadal was studied for its influence on conditions involving periods of heightened symptoms of frequent nocturnal awakenings—or difficulty staying asleep—though this was often a secondary focus in trials of the immediate-release formulation. Studies monitored outcomes such as the total Wake After Sleep Onset (WASO) and the number of times sleep was interrupted.

Research exploring these symptoms monitored measurements related to the time spent awake during the night. Some studies reported patterns observed in the active group compared to the placebo groups. The reported findings were often less pronounced than those related to sleep initiation.

Because this medicine was primarily studied for sleep onset, data for this specific type of symptom remains insufficient for the standard immediate-release formulation. The evidence quality varies across studies when maintenance is the focus, as this measure was frequently a secondary endpoint in the research.


Comparative Study Landscape and Placebo-Controlled Trials

Research examined Ivadal in numerous trials comparing it against an inactive placebo. Additionally, head-to-head research was conducted where the medicine was evaluated in comparison with other prescription sleep aids, including older classes of hypnotics.

These comparative studies were used in research exploring how symptoms change over time, specifically monitoring outcomes related to systemic or functional imbalance, such as residual sleepiness the following morning. Data show patterns related to different sleep parameters being measured between the active medicine and placebo groups. However, in studies comparing it to other active prescription drugs, comparative evidence is lacking, making broad conclusions about relative performance difficult. Head-to-head research exploring short-term symptom changes often faces challenges due to heterogeneity in study designs and the differing characteristics of the drugs being compared.

Key Studies & References

  1. Zolpidem - StatPearls (Overview of efficacy, dosing, and adverse effects)

Frequently Asked Questions (FAQ)

Common questions about Ivadal (FAQ)

Q: How quickly does Ivadal typically start to work?

Ivadal (Zolpidem) is a fast-acting medicine, consistent with its intended use for initiating sleep. Official administration instructions emphasize that due to this rapid action, the medication should only be taken when an individual is already in bed and prepared to sleep, or when experiencing difficulty falling asleep.


Q: How long do the effects of Ivadal usually last?

The active ingredient in Ivadal is eliminated from the body relatively quickly, with an average half-life of about 2.5 to 2.6 hours. Official product information advises that the medicine should only be taken when an individual is committed to getting a full night's sleep, generally defined as seven to eight hours, to help minimize next-day effects.


Q: Does Ivadal interact with over-the-counter supplements like melatonin?

Regulatory warnings indicate that combining Ivadal with other sedating agents can increase side effects such as drowsiness, confusion, and impaired motor coordination. This general warning applies to any substance that causes central nervous system (CNS) depression, including over-the-counter supplements, though specific supplements like melatonin are not always named in the primary label.


Q: What happens if a dose of Ivadal is forgotten or missed?

Official guidance indicates that a missed dose is generally skipped, and the individual should return to the regular dosing schedule the next night. The official instructions advise against doubling the dose. Ivadal is only intended to be taken when preparing to sleep and with sufficient time for a full rest period.


Q: Is it possible to develop a tolerance to the effects of Ivadal over time?

Official warnings indicate that the potential for tolerance, defined as a reduced response to the drug over time, is documented, particularly with prolonged use. Because of this risk, the potential for tolerance and dependence is explicitly associated with the duration of treatment.


Q: Is Ivadal the same type of medicine as Ambien or Lunesta?

The active ingredient in Ivadal is Zolpidem, which is the same as the active ingredient found in the brand-name drug Ambien. Both Ivadal and Lunesta (eszopiclone) belong to the same pharmacological class of non-benzodiazepine sedative-hypnotics, a group often referred to as 'Z-drugs.'


Q: Is there a generic version of Ivadal available?

Yes, the active ingredient in Ivadal, Zolpidem Tartrate, is widely available in a generic form. The generic product has been approved by the FDA as an equivalent to the brand-name product.


Q: Is it common to have strange dreams or nightmares while taking Ivadal?

Official product information lists nightmares as a possible side effect of Zolpidem, grouped under Psychiatric adverse reactions. Nightmares are generally documented as an uncommon event in clinical study populations.


Q: Can Ivadal be taken by people with kidney or liver conditions?

Regulatory documents place strict limitations on use for individuals with liver conditions, as the drug is contraindicated in those with severe hepatic insufficiency (severe liver impairment). For those with mild to moderate impairment, a lower starting dose is often recommended. Official labeling indicates that no specific dosage adjustment is recommended for patients with compromised renal (kidney) function.


Q: Does Ivadal contain any ingredients that cause allergic reactions?

Ivadal is officially contraindicated in patients with a known hypersensitivity or allergy to the active ingredient, zolpidem tartrate, or any of the inactive ingredients (excipients) in the formulation. Severe allergic reactions (e.g., anaphylaxis and angioedema) have been reported in the official safety profile, which are considered potentially serious events.


Q: Is Ivadal safe to use if I have anxiety or depression?

Official warnings note that Ivadal has central nervous system (CNS) depressant effects and carries a documented risk of potentially worsening depression or causing suicidal thoughts. Patients with pre-existing mood disorders or depression require close monitoring. While anxiety may be a listed side effect, regulatory warnings predominantly describe risk considerations related to depression.


Q: Can Ivadal be split or crushed if someone has trouble swallowing pills?

No, according to regulatory administration instructions, the immediate-release Ivadal tablets must be swallowed whole and should not be divided, crushed, or chewed. Altering the tablet is officially not recommended because it may change how the drug is absorbed by the body.


How should Ivadal be stored and disposed of?

Ivadal (zolpidem tartrate) tablets must be stored strictly according to regulatory mandates to maintain product integrity and prevent misuse.

Storage Requirements

Ivadal must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from light and moisture. The medication must be kept in a tight, light-resistant container and stored in a safe place due to its classification as a Schedule IV controlled substance. It is required to keep this and all medicines out of the reach of children.

Disposal Instructions

Unused or expired Ivadal should be disposed of through a drug take-back program. If a program is unavailable, follow the official alternative: mix the tablets with an undesirable substance, seal the mixture in a container, and discard it in household trash. All identifying information must be removed from the original container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivadal found in:

A-Z Index: